Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.
整合暴露组和甲基化组,以了解已建立的不同队列中 ADRD 的大脑分子变化。
基本信息
- 批准号:10657846
- 负责人:
- 金额:$ 98.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdministrative SupplementAffectAfrican AmericanAge FactorsAlcohol consumptionAllelesAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskAmericanAmyloidAmyloid beta-ProteinAutopsyAwardBrainBrain DiseasesBrain regionCell NucleusCellsCerebellumCerebrovascular DisordersChIP-seqClinicCohort StudiesCollaborationsCollecting CellCollectionCommunitiesComplementary DNADNADNA MethylationDataData AnalysesDiagnosisDiseaseDisease OutcomeEducationEthnic OriginEthnic groupFreezingGene ExpressionGeneticGenomic SegmentGenotypeGoalsHealthIndividualKnowledge PortalLatin AmericanLatinoLife StyleMeasuresMethylationMicrogliaMolecularMolecular ProfilingMultiomic DataNatural ImmunityNeurodegenerative DisordersNeurogliaNeuronsNot Hispanic or LatinoOutcomeParentsParticipantPathogenesisPathologyPhenotypePlayPopulationPopulation HeterogeneityProcessProgressive Supranuclear PalsyProteomeProteomicsPublicationsRaceRecordsResearchRoleSamplingSmokingSuperior temporal gyrusSystemTemporal LobeTissuesapolipoprotein E-4basebrain cellbrain healthbrain tissueburden of illnesscell typecohortcomorbiditycomparativedementia riskdesigndisorder riskepigenomeepigenomicsethnic minorityinsightlipidomicsmembermetabolomemetabolomicsmethylomemulti-ethnicmultiple omicsneuropathologynovelparent grantpathological agingracial and ethnicsexsocialsocial health determinantstau Proteinstherapeutic targettranscriptometranscriptome sequencingtranscriptomics
项目摘要
Project Summary
This is an application for an administrative supplement to enhance the outcome of the parent grant: U01
AG046139 “A Systems Approach to Targeting Innate Immunity in AD”. This Administrative Supplement aims to
expand the multiomics profiling in this cohort and enable curation of exposome variables from existing
brain bank records. The design of our unique study cohort in the parent award enables us to perform comparative
analysis of control (no pathology), PathAg, (Pathologic Aging, amyloid+), AD (tau+, amyloid+) and PSP
(progressive supranuclear palsy, tau+) providing a framework to identify therapeutic targets that play a role in
the transition to different disease neuropathologic stages of AD. Further, comparisons between two brain regions
(TCX=affected and CER=largely spared in AD) and between AD and PSP can help distinguish whether the
molecular changes identified are likely a cause or consequence of pathology. We have collected multiomics
measures in ~350 study participants, including genetic (WGS), transcriptomic (RNAseq) and epigenomic (ChIP-
Seq) data. In collaboration with other consortia members, proteomic, metabolomic and lipidomic measures
were/will also be collected. The study cohort in the parent award is focused on non-Hispanic White (NHW)
individuals. Through the AMP-AD diversity initiative supplement, we expanded this study to understudied
racial/ethnic minority cohorts comprising African American (AA) and Latin American (LA) participants. These
efforts have generated complementary genetic, transcriptomic and proteomic measures on >200 diverse
individuals. However, complementary DNA methylation data is currently lacking from both the parent (NHW)
and the diversity supplement (AA, LA) cohorts. The samples in both cohorts are from the Mayo Clinic brain bank
and have undergone in-depth neuropathological examination. A similarly in-depth review of available records to
curate data on demographic, lifestyle (education, smoking and alcohol consumption), comorbid diseases,
as well as specific neuropathological findings indicative of cerebrovascular disease is currently lacking. We
hypothesize that the exposome interacts with the epigenome to drive gene expression changes which may
underlie regional, cellular and ethno-racial vulnerabilities to neuropathology and ultimately neurodegenerative
disease. The goal of this Supplement is to extract and collect exposome and DNA methylation data respectively
for participants in the Mayo Clinic AMP-AD cohorts. Our specific aims are: 1. Identify exposome variables in an
established post-mortem cohort of multi-ethnic participants with existing and new (methylome) brain multi-omics
data. 2. Discover differentially methylated regions in brain associated with AD/ADRD diagnosis, neuropathology,
and exposome phenotypes. 3. Identify impacts of AD, related neuropathologies and exposome phenotypes on
the DNA methylation profile of key brain cell types in AD. We expect to identify differentially methylated
regions (DMRs) that reveal the molecular mechanisms underlying brain regional and cellular
vulnerabilities in AD and their interactions with exposome and race/ethnicity that may drive this.
项目摘要
这是一项行政补充申请,以提高家长补助金的结果:U01
AG046139“针对阿尔茨海默病先天免疫的系统方法”。本行政副刊旨在
在这个队列中扩展多组学分析,并支持从现有的曝光组变量中精选
脑库记录。在家长奖中我们独特的研究队列的设计使我们能够进行比较
对照(无病理)、路径抗原(病理性衰老,淀粉样蛋白+)、阿尔茨海默病(tau+,淀粉样蛋白+)和PSP的分析
(进行性核上性麻痹,tau+)提供一个框架,以确定在
阿尔茨海默病向不同疾病神经病理阶段的过渡。此外,两个大脑区域之间的比较
(TCX=在AD中受影响,CER=在AD中基本不受影响)以及AD和PSP之间的差异可以帮助区分
确认的分子变化可能是病理的原因或结果。我们收集了多组学
对约350名研究参与者的测量,包括遗传(WGS)、转录(RNAseq)和表观基因组(CHIP-
SEQ)数据。与其他联盟成员合作,蛋白质组、代谢组和脂肪组学措施
我们/将也会被收集。家长奖中的研究队列集中在非西班牙裔白人(NHW)
个人。通过AMP-AD多样性倡议补充,我们将这项研究扩展到未被研究
由非洲裔美国人(AA)和拉丁美洲人(LA)参与者组成的种族/少数民族队列。这些
努力已经在200种不同的基因、转录和蛋白质组学方面产生了互补的措施
个人。然而,目前缺乏来自亲本(Nhw)的互补DNA甲基化数据。
和多样性补充(AA,LA)队列。两个队列中的样本都来自梅奥诊所脑库
并接受了深入的神经病理检查。对现有记录进行类似的深入审查,以
整理人口统计、生活方式(教育、吸烟和饮酒)、并存疾病、
以及指示脑血管疾病的特定神经病理结果目前尚不清楚。我们
假设曝光组与表观基因组相互作用,以驱动基因表达变化,这可能
导致神经病理和最终神经退行性变的区域性、细胞性和种族脆弱性
疾病。本附录的目标是分别提取和收集曝光组和DNA甲基化数据
梅奥诊所AMP-AD队列的参与者。我们的具体目标是:1.在一个
用现有的和新的(甲基组)脑多组学建立了多种族参与者的尸检队列
数据。2.发现大脑中与AD/ADRD诊断、神经病理学、
并暴露出一些表型。3.确定阿尔茨海默病、相关神经病理和暴露表型对
阿尔茨海默病关键脑细胞类型的DNA甲基化图谱。我们希望发现差异甲基化
揭示大脑区域和细胞的分子机制的区域(DMR)
AD中的漏洞及其与Exposome和种族/民族的交互可能会推动这一点。
项目成果
期刊论文数量(77)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Dense data enables 21st century clinical trials.
- DOI:10.1002/trc2.12297
- 发表时间:2022
- 期刊:
- 影响因子:4.8
- 作者:Roach, Jared C;Hodes, John F;Funk, Cory C;Shankle, William R;Merrill, David A;Hood, Leroy;Bramen, Jennifer
- 通讯作者:Bramen, Jennifer
A systems-biology clinical trial of a personalized multimodal lifestyle intervention for early Alzheimer's disease.
- DOI:10.1002/trc2.12191
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:McEwen SC;Merrill DA;Bramen J;Porter V;Panos S;Kaiser S;Hodes J;Ganapathi A;Bell L;Bookheimer T;Glatt R;Rapozo M;Ross MK;Price ND;Kelly D;Funk CC;Hood L;Roach JC
- 通讯作者:Roach JC
Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains.
- DOI:10.1186/s13024-016-0137-9
- 发表时间:2016-11-25
- 期刊:
- 影响因子:15.1
- 作者:Ma L;Allen M;Sakae N;Ertekin-Taner N;Graff-Radford NR;Dickson DW;Younkin SG;Sevlever D
- 通讯作者:Sevlever D
Handgrip Strength Is Related to Hippocampal and Lobar Brain Volumes in a Cohort of Cognitively Impaired Older Adults with Confirmed Amyloid Burden.
- DOI:10.3233/jad-220886
- 发表时间:2023
- 期刊:
- 影响因子:4
- 作者:Meysami, Somayeh;Raji, Cyrus A.;Glatt, Ryan M.;Popa, Emily S.;Ganapathi, Aarthi S.;Bookheimer, Tess;Slyapich, Colby B.;Pierce, Kyron P.;Richards, Casey J.;Lampa, Melanie G.;Gill, Jaya M.;Rapozo, Molly K.;Hodes, John F.;Tongson, Ynez M.;Wong, Claudia L.;Kim, Mihae;Porter, Verna R.;Kaiser, Scott A.;Panos, Stella E.;Dye, Richelin, V;Miller, Karen J.;Bookheimer, Susan Y.;Martin, Neil A.;Kesari, Santosh;Kelly, Daniel F.;Bramen, Jennifer E.;Siddarth, Prabha;Merrill, David A.
- 通讯作者:Merrill, David A.
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
- DOI:10.1111/jnc.13583
- 发表时间:2016-10
- 期刊:
- 影响因子:4.7
- 作者:Golde TE
- 通讯作者:Golde TE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NILUFER ERTEKIN-TANER其他文献
NILUFER ERTEKIN-TANER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NILUFER ERTEKIN-TANER', 18)}}的其他基金
Discovering Centrally Linked Peripheral Molecular Signatures of Alzheimer's Disease
发现阿尔茨海默病的中心连锁外周分子特征
- 批准号:
10555727 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
- 批准号:
10246077 - 财政年份:2020
- 资助金额:
$ 98.9万 - 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
- 批准号:
10475289 - 财政年份:2020
- 资助金额:
$ 98.9万 - 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
- 批准号:
10251376 - 财政年份:2020
- 资助金额:
$ 98.9万 - 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
- 批准号:
10506095 - 财政年份:2020
- 资助金额:
$ 98.9万 - 项目类别:
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD
利用弹性分子网络进行 AD 治疗发现
- 批准号:
10404635 - 财政年份:2018
- 资助金额:
$ 98.9万 - 项目类别:
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD
利用弹性分子网络进行 AD 治疗发现
- 批准号:
10170201 - 财政年份:2018
- 资助金额:
$ 98.9万 - 项目类别:
相似海外基金
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
- 批准号:
10833895 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
- 批准号:
10841820 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
- 批准号:
10850135 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
- 批准号:
10896844 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
- 批准号:
10840220 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
- 批准号:
10844667 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
- 批准号:
10891050 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
- 批准号:
10711717 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
- 批准号:
10811292 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:
Administrative Supplement: Genome Resources for Model Amphibians
行政补充:模型两栖动物基因组资源
- 批准号:
10806365 - 财政年份:2023
- 资助金额:
$ 98.9万 - 项目类别:














{{item.name}}会员




